Lack of prevention of large intestinal cancer by VPS, an extract of Coriolus versicolor mushroom

In Vivo

Volumn 19, Issue 5, 2005, Pages 867-872

  Coles, Melissa ^a   Toth, Bela ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cancer prevention; Intestine; Mushroom extract

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CORIOLUS VERSICOLOR EXTRACT; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; CORIOLUS VERSICOLOR; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; MOUSE; MUSHROOM; NONHUMAN; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 23044482916     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Borchers AT, Stern JS, Hackman RM, Keen CL and Gershwin ME: Mushrooms, tumors, and immunity. Proc Soc Exp Bio Med 221: 281-293, 1999.
2. Ng TB: A review of research on the protein-bound polysaccharide (polysaccaropeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). Gen Pharmacol 30: 1-4, 1998.
3. Wasser SP and Weis AL: Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol 19: 65-96, 1999.
4. Sakita M, Imai H, Kasuga M, Kageyama N, Imaki K, Tamai M, Fujita Y and Majima S: Effect of a protein-bound polysaccharide preparation, PS-K, on dimethyl hydrazine induction of intestinal tumors in rats. Gann 74: 351-359, 1983.
5. Nakajima T, Ichikawa S, Uchida S and Komada T: Effects of a protein-bound polysaccharide from a basidiomycetes against hepatocarcinogenesis induced by 3′-methyl-4-dimethylamino-azobenzene in rats. Clin Ther 12: 385-392, 1990.
6. Hosokawa M, Mizukoshi T, Morikawa K, Xu ZY and Kobayashi H: The therapeutic effects of an immunopotentiator, PSK, on 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice in combination with the surgical removal of primary site. Cancer Immunol Immunother 22: 181-185, 1986.
7. Nagao T, Komatsuda M, Yamauchi K, Nozaki H, Watanabe K and Arimori S: Chemoimmunotherapy with Krestin in acute leukemia. Tokai J Exp Clin Med 6: 141-146, 1981.
8. Ohno R, Yamada K, Masaoka T, Ohshima T, Amaki I, Hirota Y, Horikoshi N, Horiuchi A, Imai K, Kimura I, Kitajima K, Nakamura H, Nakamura T, Ohta Y, Sakai Y, Tanaka M, Tsubaki K, Uchino H, Ogawa N and Kimura K: A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation. Cancer Immunol Immunother 18: 149-154, 1984.
9. Go P and Chung CH: Adjuvant PSK immunotherapy in patients with carcinoma of the nasopharynx. J Int Med Res 17: 141-149, 1989.
10. Torisu M, Hayashi Y, Ishimitsu T, Fujimura T, Iwasaki K, Katano M, Yamamoto H, Kimura Y, Takesue M, Kondo M and Nomoto K: Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immuno Immunother 31: 261-268, 1990.
11. Toi M, Hattori T, Akagi M, Inokuchi K, Orita K, Sugimachi K, Dohi K, Nomura Y, Monden Y, Hamada Y, Morimoto T and Ogawa N: Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer 70: 2475-2483, 1992.
12. Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K, Nishiyama K, Amano T, Takahashi T, Murayama N, Oka H, Oya K, Noto T and Ogawa N: Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum 35: 123-130, 1992.
13. Hayakawa K, Mitsuhashi N, Saito Y, Takahashi M, Katano S, Shiojima K, Furuta M and Niibe H: Effect of krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res 13: 1815-1820, 1993.
14. Nakazato H, Koike A, Saji S, Ogawa N and Sakamoto J: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343: 1122-1126, 1994.
15. Iino Y, Yokoe T, Maemura M, Horiguchi J, Takei H, Ohwada S and Morishita Y: Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res 15: 2907-2911, 1995.
16. Sugimachi K, Maehara Y, Ogawa M, Kakegawa T and Tomita M: Dose intensity of uracil and tegafur in postoperative chemotherapy patients with poorly differentiated gastric cancer. Cancer Chemother Parmacol 40: 233-238, 1997.
17. Altman DG: Practical Statistics for Medical Research. Chapter 9: Comparing groups-continuous data. Chapman & Hall, New York, pp. 194-215, 1991.
18. Toth B, Malick L and Shimizu H: Production of intestinal and other tumors by 1,2-dimethylhydrazine dihydrochloride in mice. I. A light transmission electron microscopic study of colonic neoplasms. Am J Pathol 84: 69-86, 1976.
19. Toth B, Magee PN and Shubik P: Carcinogenesis study with dimethylnitrosamine administered orally to adult and subcutaneously to newborn BALB/c mice. Cancer Res 24: 1712-1721, 1974.
20. Toth B and Shimizu H: 1-Carbamyl-2-phenylhydrazine tumorigenesis in Swiss mice. Morphology of lung adenomas. J Natl Cancer Inst 52: 241-251, 1974.
21. Toth B, Rappaport H and Shubik P: The influence of dose and age on the induction of malignant lymphomas and other tumors by 7,12-dimethylbenz(a)anthracene in Swiss mice. J Natl Cancer Inst 30: 723-741, 1963.